DOCSLIB.ORG

Influence of Anti-Inflammatory Flavonoids on Degranulation And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influence of Anti-Inflammatory Flavonoids on Degranulation And Influence of Anti-Inflammatory Flavonoids on Degranulation and Arachidonic Acid Release in Rat Neutrophils Marí a Tordera, Marí a Luisa Ferrándiz and María José Alcaraz Departamento de Farmacologia de la Universidad de Valencia, Facultad de Farmacia, Avda. Vicent Estelles s/n, 46100 Burjassot, Valencia, Spain Z. Naturforsch. 49c, 235-240 (1994); received December 30, 1993 Flavonoids, Anti-Inflammatory Flavonoids, Arachidonic Acid, Lysosomal Enzymes, Rat N eutrophil We assessed the effects of 24 flavonoid derivatives, reported as anti-inflammatory, on lyso­ somal enzyme secretion and arachidonic acid release in rat neutrophils. Amentoflavone, quer- cetagetin-7-O-glucoside, apigenin, fisetin, kaempferol, luteolin and quercetin were the most potent inhibitors of ß-glucuronidase and lysozyme release. The first compound was also able to inhibit basal release. These flavonoids besides chrysin and to a reduced extent, naringenin, significantly inhibited arachidonic acid release from membranes. A correlation between de­ granulation and arachidonic acid release was found for this series of compounds. Structure- activity relationships and implications for the anti-inflammatory effects of these flavonoids were discussed. Introduction of flavonoids on reactive oxygen species genera­ Besides a wide range of biological activities tion in neutrophils (Limasset et al., 1993). (Havsteen, 1983) some members of the flavonoid Secretion is a crucial event induced by leukocyte class display anti-inflammatory effects in animals activation and resulting in the release of degrada- (Alcaraz and Jimenez, 1988; Ferrändiz and Alca­ tive enzymes which play an important role in tissue raz, 1991). The mechanism of action is unclear but damage during inflammation. There are several it may involve the inhibition of eicosanoids prod­ possible links between arachidonic acid release uction by intact cells with different selectivity to­ and secretion. Thus, products derived from PLA2 wards cyclo-oxygenase or lipoxygenase pathways activity could be required for the fusion of lyso- depending on their structural features (Moroney somes and plasma membranes, or arachidonic acid et al., 1988). Other actions possibly account for the released would induce degranulation and other molecular mechanisms leading to control the in­ neutrophil responses (Smolen and Weissmann, flammatory process. As suggested for many non­ 1993). steroidal anti-inflammatory agents (Smolen and The objective of this study was to obtain evi­ dence as to whether a series of flavonoids endowed Weissmann, 1993; Kaplan et al., 1984; Neal et al., 1987; Smolen et al., 1991; Inoue et al., 1991; Zim- with anti-inflammatory properties, modify select­ merli et al., 1991) the suppression of leukocyte ed neutrophil responses which contribute to the in­ functions may provide a basis for the anti-inflam­ flammatory process. Thus, we have investigated matory effects of flavonoids. In this respect, recent the capacity of a series of flavonoids to inhibit de­ attention has focused upon the inhibitory effects granulation in rat neutrophils and we have includ­ ed as reference some compounds, like quercetin, previously reported as inhibitors of leukocyte functions in other species (Bennett et al., 1981; Middleton Jr. et al., 1987; Showell et al., 1981; Abbreviations: BSA, bovine serum albumin; DM SO, Blackburn et al., 1987; Berton et al., 1980). In dimethyl sulfoxide; F M L P, N-formyl-L-methionyl- order to understand better the modification of L-leucyl-L-phenylalanine; PBS, phosphate buffer saline; eicosanoid generation by flavonoids in relevant in­ PLA 2, phospholipase A 2; PLC, phospholipase C; PLD, phospholipase D. flammatory cells, we have also assessed in the Reprint requests to Prof. Maria Jose Alcaraz. present study the influence of these flavonoids on the release of arachidonic acid from leukocyte Verlag der Zeitschrift für Naturforschung, D-72072 Tübingen membranes, a process mainly dependent on PLA2 0939-5075/94/0300-0235 $03.00/0 activity. 236 M. Tordera et al. ■ Flavonoids and Selected Rat Neutrophil Functions Materials and Methods Arachidonic acid release (Croft et al., 1987) Drugs Cells were suspended in Hank's solution at a Sideritoflavone was isolated from Sideritis leu- concentration of 107 ml and incubated with arachi­ cantha and hypolaetin-8-O-glucoside from Sideri­ donic acid (0.1 |iCi/ml) for 60 min at 37 °C. Leu­ tis mugronensis, following known procedures (Vil- kocytes were then washed in PBS three times and lar et al., 1985; Jimenez et al., 1986). Oroxindin resuspended in H ank’s solution + 0.1 % BSA. Test from Oroxylum indicum; quercetagetin-7-O-gluco- compounds were preincubated for 15 min at 37 °C side from Tagetes erecta, gossypin and hibifolin before addition of ionophore A 23187 (25 (ig/ml). from Hibiscus vitifolius, and tambuletin from After 10 min, tubes were placed on ice and centri­ Zhanthoxylum alatum were a gift from Prof. fuged as above. Radioactivity was determined in A. G. R. Nair (Pondicherry University, India). supernatants by liquid scintillation counting. Other flavonoids were commercially available: fla- Results were expressed as means ± SE for 3-6 vone, 3-hydroxyflavone and fisetin (Aldrich); tro- determinations. Compounds able to inhibit con­ xerutin (Almirall); quercetin (Merck); apigenin, lu- trol reactions at least by 50% were tested over a teolin and amentoflavone (Roth); leucocyanidol range of concentrations to determine their half- (Rovi); chrysin, rutin, morin, naringenin, naringin, maximal inhibitory concentration. Statistical (+)-catechin, (-)-epicatechin and kaempferol analysis was performed by using the Dunnett’s (Sigma). [14C]-arachidonic acid (100|iCi/ml) was t-test. purchased from DuPont. Ionophore A 23187, BSA, glycogen, cytochalasin B, FMLP and triton X-100 were purchased from Sigma. The rest of the Results chemicals were of analytical grade. In control incubations, the extent of lysozyme secretion was more than twice that of ß-glucuroni- dase either in the presence or in the absence of sti­ Isolation of leukocytes mulus (data not shown). A number of flavonoids Rat peritoneal leukocytes elicited by glycogen inhibited ß-glucuronidase and lysozyme release, (10 ml, 1%) were prepared by centrifugation and taken as markers of rat peritoneal leukocytes de­ hypotonic lysis of contaminating red cells (Moro- granulation (Table I). Amentoflavone, querceta- ney et al., 1988). The cell suspension contained getin-7-O-glucoside, apigenin, fisetin, kaempferol, 90% neutrophils and viability was greater than luteolin and quercetin yielded more than 60% of 95% assessed by Trypan blue exclusion. inhibition on both enzymes secretion. Besides, oroxindin, chrysin and hibifolin affected selective­ ly ß-glucuronidase release. The regression analysis of the curves obtained for these active compounds, Lysosomal enzyme secretion showing more than 60% of inhibition at 10"4 m , at Leukocytes were suspended at 6 x 106 cells/ml in a range of concentrations between 10“5 m and PBS and preincubated for 8 min at 37 °C with 10~4m (or 10“6m and 10-4m for amentoflavone), cytochalasin B (5 |ig/ml) followed by addition of allowed us the calculation of the inhibitory con­ test compound or vehicle (10|il DMSO). After centration 50% (IC50). Amentoflavone showed the 8 min, FMLP (10-6 m ) was added and incubation highest potency, especially for inhibition of ß-gluc- proceeded for 8 min. The cell suspensions were uronidase release, with an IC50 in the [IM range then placed on ice and centrifuged at 3000 r.p.m. (Fig. 1). At concentrations between 3 x 10-5 m and for 15 min at 4 °C. ß-Glucuronidase and lysozyme 1 0 -4 m amentoflavone gave percentages of inhibi­ levels in supernatants were determined by spectro- tion for ß-glucuronidase release higher than 100%, photometric procedures previously described indicating its ability to influence degranulation in (Gianetto and de Duve, 1955; Yuli et al., 1982) and basal conditions (in the absence of any stimulus). results were expressed as percentage of release with In this case, its IC50 was 4.5±0.1 x 10~5 m and respect to tubes treated with 10 |il 20% triton 6.2 ± 0.4 x 10'4 m, for ß-glucuronidase and lyso­ X-100. zyme basal release, respectively. For most com- M. Tordera et al. • Flavonoids and Selected Rat Neutrophil Functions 237 Table I. Structure of the flavonoids tested. Effect on leukocyte degranulation: percentage of inhibition at 10 4 m (% I) and inhibitory concentration 50% ( i c 50). 3' ß-Glucuronidase Lysozyme 5 m) % I IC50 (x 10~5 m) vones r 5 r 6 r 7 r 8 Ry R, % I IC50(xlO - vone H HHHH H 56.7 ±2.9** N.D. 32.6 ± 1.0** N.D. rysin OH H OH H H H 72.0± 4.8** 6.6 ±0.9 51.7 ± 3.3** N.D. igenin OH H OH H H OH 92.9 ±4.0** 2.6 ± 0.3 71.8 ± 3.3** 6.5 ±0.7 eolin OH H OH H OH OH 90.9 ±3.0** 3.5 ± 1.2 72.0 ± 1.3** 4.6 ±0.3 eritoflavone OH o c h 3 OCH, OCHj OH OH 32.7 ±2.1** N.D. 11.0 ±5.9 N.D. polaetin-8-O-Gl OH H OH OG1 OH OH 2.0 ± 2 .2 N.D. 12.2 ±2.4 N.D. )xindin OH H OGlr OCHj H H 70.8 ±3.1** 7.4 ± 1.1 44.3 ±2.0** N.D. ß-Glucuronidase Lysozyme r 2. r 3. % I IC jotx 10- 5 m) % 1 IC50 (X 10-5 M) vonols r 3 R-5 r 7 Rs r 4 fydroxyflavone OH H HHHH H H --103.2 ± 2.1** 6.7 ±0.7 -5 4 .2 ± 6.5** N.D. etin OH H H OH H H OH OH 100.0 ± 5.2** 2.3 ±0.3 101.7 ± 14.2** 3.3 ±0.2 empferol OH OH H OH H H H OH 74.4 ± 3.7** 4.5 ± 1.2 75.8 ± 8.9** 2.9 ±0.8 ercetin OH OH H OH H H OH OH 90.4± 0.9** 2.4 ±0.1 88.5 ± 2.7** 2.1 ± 0 .2 >rin OH OH H OH H OH H OH 36.3 ± 7.0** N.D.
Load more

Recommended publications
  • Therapeutic Potential of Flavonoids in Inflammatory Bowel Disease: a Comprehensive Review
    Submit a Manuscript: http://www.f6publishing.com World J Gastroenterol 2017 July 28; 23(28): 5097-5114 DOI: 10.3748/wjg.v23.i28.5097 ISSN 1007-9327 (print) ISSN 2219-2840 (online) REVIEW Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review Ali Salaritabar, Behrad Darvishi, Farzaneh Hadjiakhoondi, Azadeh Manayi, Antoni Sureda, Seyed Fazel Nabavi, Leo R Fitzpatrick, Seyed Mohammad Nabavi, Anupam Bishayee Ali Salaritabar, Behrad Darvishi, Department of Integrative work non-commercially, and license their derivative works on Oncology, Breast Cancer Research Center, Motamed Cancer different terms, provided the original work is properly cited and Institute, ACECR, Tehran 15179-64311, Iran the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/ Ali Salaritabar, Behrad Darvishi, Department of Recombinant Protein, Breast Cancer Research Center, Motamed Cancer Manuscript source: Invited manuscript Institute, ACECR, Tehran 15179-64311, Iran Correspondence to: Anupam Bishayee, PhD, Department Farzaneh Hadjiakhoondi, Azadeh Manayi, Medicinal Plants of Pharmaceutical Sciences, College of Pharmacy, Larkin Research Center, Faculty of Pharmacy, Tehran University of University, Miami, FL 33169, Medical Sciences, Tehran 14176-14411, Iran United States. [email protected] Telephone: +1-305-7607511 Antoni Sureda, Research Group on Community Nutrition and Oxidative Stress and CIBEROBN - Physiopathology of Obesity Received: February 16, 2017 and Nutrition, University of Balearic Islands, Palma
    [Show full text]
  • Current Perspectives on Medicinal and Aromatic Plants
    Review Curr. Pers. MAPs, (2021); 4(1): 66-86 Current Perspectives on Medicinal and Aromatic Plants An International Journal ISSN: 2619-9645 | e-ISSN: 2667-5722 Prevention of Viral Effect and Enhancement of Immune System with the help of Herbal Plants and Himalayan Crude Drugs in SAR-COV-2 Patient: A Review Rishiram BARAL1,2 1Department of Pharmaceutical Sciences, School of Health and Allied Sciences, Faculty of Health Science, Pokhara University, Pokhara, Nepal 2Research Institute of Pharmaceutical Sciences, Department of Pharmacy, Kyungpook National University, Daegu, South Korea *Corresponding author: [email protected] Received : 07/06/2021 https://doi.org/ 10.38093/cupmap.948975 Accepted : 30/06/2021 Abstract After December 2019, Severe Acute Respiratory Syndrome (SAR-COV-2) become a life-threatening issue to the entire human society when it started to spread exponentially all over the world from Wuhan city of China. The virus directly hits the upper and lower respiratory tract of human airways and causes severe damage to the human lung, leading to multiorgan failure, hypoxemia, and dyspnea. Similarly, studies revealed that SAR-COV-2 severely hit the younger and aged population in which the immune system is seriously compromised. The cell of the immune system such as T-cells, B-cells, NK cells, etc. helps to fight against such viral antigen and resist critical viral damage. Therefore, enhancement of the immune system could also be an effective approach to prevent viral infection and even aid in the reduction of the death count. Nowadays, dietary, and herbal remedies are being integrated into the mainstream of the healthcare systems because of their multi-ingredient character, and some of them are known to render efficacy comparable to that of synthetic drug substances.
    [Show full text]
  • Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The
    Appendix 1 – Protocol for Preventing or Reversing Chronic Disease The first author has developed a protocol over the past decade for preventing or reversing chronic disease based on the following systemic medical principle: “at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective”[1]. The protocol methodology refines the age-old principles of both reducing harm in addition to providing treatment, and allows better identification of factors that contribute to the disease process (so that they may be eliminated if possible). These contributing factors are expansive and may include a combination of Lifestyle choices (diet, exercise, smoking), iatrogenic and biotoxin exposures, environmental/occupational exposures, and psychosocial stressors. This strategy exploits the existing literature to identify patterns of biologic response using biomarkers from various modalities of diagnostic testing to capture a much broader list of potential contributing factors. Existing inflammatory bowel diseases (IBD) Biomarker Identification to Remove Contributing Factors and Implement Treatment The initial protocol steps are diagnostic. The main output of these diagnostics will be identification of the biomarker levels and symptoms that reflect abnormalities, and the directions of change required to eliminate these abnormalities. In the present study, hundreds of general and specific biomarkers and symptoms were identified from the core IBD literature. The highest frequency (based on numbers of record appearances) biomarkers and symptoms were extracted, and are listed in Table 1 (highest frequency items first, reading down each column before proceeding to the next column). They are not necessarily consensus biomarkers. They are biomarkers whose values were altered by a treatment or contributing factor, and reported in the core IBD literature.
    [Show full text]
  • An Avowal of Importance of Endangered Tree Oroxylum Indicum (Linn.) Vent
    Article An avowal of importance of endangered tree Oroxylum indicum (Linn.) Vent. M Gokhale and Y K Bansal* Department of Bioscience, R.D. University, Jabalpur-482 001, Madhya Pradesh, India *Correspondent author Received 2 May 2005; Accepted 5 July 2005 Abstract A small deciduous tree Oroxylum indicum (Linn.) Vent. of family Bignoniaceae, also known as Shivnak, Sonapatha, Shyonaka or Midnight horror possesses economic as well as medicinal importance. The tree was distributed throughout the greater part of India but now it is listed amongst endangered species in many areas in the country. Its conservation is urgently required. Keywords : Shivnak, Sonapatha, Shyonaka, Midnight horror, Oroxylum indicum, Medicinal plant, Endangered tree, Conservation. 7 IPC code; Int. cl. ⎯ A61K 35/78, A01G 23/00 Leaf arrangement on rachis Introduction large (90-180 cm long) and 2-3 pinnate. are numerous, reddish purple outside and Leaflet rachis is very soft and swollen at dull or pale yellow pinkish inside; Deforestation has resulted in a the junction of the branches. Leaflets are arranged in large erect racemes. Fruit is a serious damage to biodiversity and gene in 2-4 pairs, ovate, elliptic or acuminate long woody capsule up to 1m in length, resources1, 2. Naturally grown forests have in shape and glabrous in texture. Flowers containing numerous papery, flat, winged, lost many tree species and Shivnak, light seeds. The fresh root bark is soft and Oroxylum indicum (Linn.) Vent. is juicy and creamish yellow to greyish in one of them. Shivnak grows in India, colour. The taste is sweet initially later Sri Lanka, South China, Celebes, becoming bitter.
    [Show full text]
  • Ep 3138585 A1
    (19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S.
    [Show full text]
  • Pharmacokinetics of B-Ring Unsubstituted Flavones
    pharmaceutics Review Pharmacokinetics of B-Ring Unsubstituted Flavones Robert Ancuceanu 1, Mihaela Dinu 1,*, Cristina Dinu-Pirvu 2, Valentina Anu¸ta 2 and Vlad Negulescu 3 1 Department of Pharmaceutical Botany and Cell Biology, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 2 Department of Physical Chemistry and Colloidal Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest 020956, Romania 3 Department of Toxicology, Clinical Pharmacology and Psychopharmacology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania * Correspondence: [email protected]; Tel.: +40-21-318-0746 Received: 3 July 2019; Accepted: 23 July 2019; Published: 1 August 2019 Abstract: B-ring unsubstituted flavones (of which the most widely known are chrysin, baicalein, wogonin, and oroxylin A) are 2-phenylchromen-4-one molecules of which the B-ring is devoid of any hydroxy, methoxy, or other substituent. They may be found naturally in a number of herbal products used for therapeutic purposes, and several have been designed by researchers and obtained in the laboratory. They have generated interest in the scientific community for their potential use in a variety of pathologies, and understanding their pharmacokinetics is important for a grasp of their optimal use. Based on a comprehensive survey of the relevant literature, this paper examines their absorption (with deglycosylation as a preliminary step) and their fate in the body, from metabolism to excretion. Differences among species (inter-individual) and within the same species (intra-individual) variability have been examined based on the available data, and finally, knowledge gaps and directions of future research are discussed.
    [Show full text]
  • PHYTOPLAN® Pflanzliche Wirkstoffe Und Analytik
    Version 2/2016 PHYTOPLAN® Pflanzliche Wirkstoffe und Analytik Produktliste 2016 Referenzsubstanzen Naturstoffe PHYTO PLAN Diehm & Neuberger GmbH Im Neuenheimer Feld 515 D-69120 Heidelberg Tel.: 0 62 21 / 40 13 47 Fax: 0 62 21 / 43 76 64 E-Mail: [email protected] Internet: www.Phytoplan.de PHYTO PLAN Sehr geehrte Kundin, sehr geehrter Kunde, liebe Interessenten , in unsere aktuelle Produktliste haben wir auch dieses Jahr eine Reihe neuer Verbindungen aufgenommen. Über den jeweils aktuellen Umfang der Substanzliste können Sie sich auch im Internet unter www.Phytoplan.de informieren. PhytoPlan ist ein Unternehmen, das sich seit über 20 Jahren auf die Gewinnung von sekundären Pflanzeninhaltsstoffen spezialisiert hat. PhytoPlan bietet dem Kunden auf dem Naturstoffsektor ein günstiges und stetig wachsendes Angebot an analytisch dokumentierten Substanzen. Von Beginn an wurde größtes Augenmerk auf eine konstant hohe Qualität und eine umfassende Dokumentation gerichtet. Im unserem Angebot finden Sie ein weites Feld an Qualitäten, angefangen von der Rohsubstanz geringerer Reinheit bis hin zur Referenzsubstanz höchster Qualität. Viele Substanzen sind in unterschiedlichen Reinheitsstufen erhältlich. Auf Wunsch kann bei jeder Substanz eine an den Bedarf angepasste Dokumentation angeboten werden. Da wir alle Substanzen im eigenen Hause herstellen, finden Sie bei uns immer einen kompetenten Ansprechpartner bei Fragen zur Gewinnung und Analytik. Aufgrund der Erfahrung mit unterschiedlichsten Substanzklassen können wir flexibel und kompetent auf Ihren Bedarf eingehen. Wir möchten uns an dieser Stelle bei unseren treuen Kunden bedanken. Falls Sie uns noch nicht kennen, würden wir uns freuen, wenn wir Ihr Interesse an unseren Produkten geweckt haben. Sollten Sie Fragen und Anregungen haben, setzen Sie sich einfach mit uns in Verbindung.
    [Show full text]
  • WO 2018/002916 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/002916 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C08F2/32 (2006.01) C08J 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C08G 18/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/IL20 17/050706 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 26 June 2017 (26.06.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 246468 26 June 2016 (26.06.2016) IL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: TECHNION RESEARCH & DEVEL¬ UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, OPMENT FOUNDATION LIMITED [IL/IL]; Senate TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, House, Technion City, 3200004 Haifa (IL).
    [Show full text]
  • In Silico and in Vitro Anti-Helicobacter Pylori Effects of Combinations Of
    molecules Article In Silico and In Vitro Anti-Helicobacter Pylori Effects of Combinations of Phytochemicals and Antibiotics Pedro Fong, Chon-Hou Hao, Chi-Cheng Io, Pou-Io Sin and Li-Rong Meng * School of Health Sciences and Sports, Macao Polytechnic Institute, Macao, China; [email protected] (P.F.); [email protected] (C.-H.H.); [email protected] (C.-C.I.); [email protected] (P.-I.S.) * Correspondence: [email protected] Academic Editor: Raphaël E. Duval Received: 10 September 2019; Accepted: 4 October 2019; Published: 7 October 2019 Abstract: Helicobacter pylori infection is a WHO class 1 carcinogenic factor of gastric adenocarcinoma. In the past decades, many studies have demonstrated the increasing trend of antibiotic resistance and pointed out the necessity of new effective treatment. This study was aimed at identifying phytochemicals that can inhibit H. pylori and possibly serve as adjuvant treatments. Here, in silico molecular docking and drug-like properties analyses were performed to identify potential inhibitors of urease, shikimate kinase and aspartate-semialdehyde dehydrogenase. These three enzymes are targets of the treatment of H. pylori. Susceptibility and synergistic testing were performed on the selected phytochemicals and the positive control antibiotic, amoxicillin. The in-silico study revealed that oroxindin, rosmarinic acid and verbascoside are inhibitors of urease, shikimate kinase and aspartate-semialdehyde dehydrogenase, respectively, in which, oroxindin has the highest potency against H. pylori, indicated by a minimum inhibitory concentration (MIC) value of 50 µg/mL. A combination of oroxindin and amoxicillin demonstrated additive effects against H. pylori, as indicated by a fractional inhibitory concentration (FIC) value of 0.75.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse Et Al
    US 20120208890A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse et al. (43) Pub. Date: Aug. 16, 2012 (54) STABLE HYDROGEL COMPOSITIONS of application No. 127956,542, filed on Nov.30, 2010, INCLUDING ADDITIVES which is a continuation-in-part of application No. 12/714,377, filed on Feb.26, 2010, which is a continu (75) Inventors: Cecile Gousse, Dingy Saint Clair ation-in-part of application No. 12/687,048, filed on (FR); Pierre F. Lebreton, Annecy Jan. 13, 2010. (FR); Nicolas Prost, Mornant (FR): Sumit Paliwal, Goleta, CA (US); Publication Classification Dennis Van Epps, Goleta, CA (US) (51) Int. C. (73) Assignee: ALLERGAN, INC. Irvine, CA A6IR 8/4I (2006.01) (US) A61O 19/08 (2006.01) A6IR 8/42 (2006.01) (21) Appl. No.: 13/350,518 (52) U.S. Cl. ......................................... 514/626; 514/653 (22) Filed: Jan. 13, 2012 (57) ABSTRACT Related U.S. Application Data The present specification generally relates to hydrogel com (63) Continuation-in-part of application No. 13/005,860, positions and methods of treating a soft tissue condition using filed on Jan. 13, 2011, which is a continuation-in-part Such hydrogel compositions. Patent Application Publication Aug. 16, 2012 Sheet 1 of 7 US 2012/0208890 A1 lication Publication ug. 16, 2012 Sheet 2 of 7 co & S. N SESo 9 CD s Y NI C O O CN ve ve D an an 5 S. 5 3. 9. S. Patent Application Publication Aug. 16, 2012 Sheet 3 of 7 US 2012/0208890 A1 00Z?000).00800900700Z0 O.GZ?eSÅep~ Patent Application Publication Aug.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0224164 A1 Lebreton (43) Pub
    US 20110224164A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0224164 A1 Lebreton (43) Pub. Date: Sep. 15, 2011 (54) FLUID COMPOSITIONS FOR IMPROVING Publication Classification SKIN CONDITIONS (51) Int. Cl. (75) Inventor: Pierre F. Lebreton, Annecy (FR) 3G 0.O :08: (73) Assignee: Allergan Industrie, SAS, Pringy (FR) (52) U.S. Cl. .......................................................... 514/54 (21)21) Appl. NoNo.: 12/777,1069 (57) ABSTRACT (22) Filed: May 10, 2010 The present specification discloses fluid compositions com O O prising a matrix polymerand stabilizing component, methods Related U.S. Application Data of making Such fluid compositions, and methods of treating (60) Provisional application No. 61/313,664, filed on Mar. skin conditions in an individual using Such fluid composi 12, 2010. tions. Patent Application Publication Sep. 15, 2011 Sheet 1 of 3 US 2011/0224164 A1 girl is" . .... i E.- &;',EE 3 isre. fire;Sigis's Patent Application Publication Sep. 15, 2011 Sheet 2 of 3 US 2011/0224164 A1 Wiscosity"in a a set g : i?vs. iii.tige: ssp. r. E. site is Patent Application Publication Sep. 15, 2011 Sheet 3 of 3 US 2011/0224164 A1 Fi; ; ; ; , ; i 3 -i-...-- m M mommam mm M. M. MS ' ' s 6. ;:S - - - is : s s: s e 3. 83 8 is is a is É . ; i: ; ------es----- .- mm M. Ma Yum YM Mm - m - -W Mmm-m a 'm m - - - S. 'm - i. So m m 3 - - - - - - - - --- f ; : : ---- ' - - - - - - - - - - - - - - - . : 2. ----------- US 2011/0224164 A1 Sep. 15, 2011 FLUID COMPOSITIONS FOR IMPROVING 0004. The fluid compositions disclosed in the present SKIN CONDITIONS specification achieve this goal.
    [Show full text]
  • Integrating Study on Qualitative and Quantitative Characterization of the Major Constituents in Shuanghuanglian Injection with UHPLC/Q-Orbitrap-MS and UPLC-PDA
    Hindawi Journal of Analytical Methods in Chemistry Volume 2021, Article ID 9991363, 11 pages https://doi.org/10.1155/2021/9991363 Research Article Integrating Study on Qualitative and Quantitative Characterization of the Major Constituents in Shuanghuanglian Injection with UHPLC/Q-Orbitrap-MS and UPLC-PDA Gen Xue ,1,2 Meijuan Zhu ,1,2 Ning Meng,1,2 Jianli Guan,3 Jide Zhang,3 Jing Yang,1,2 Yuefei Wang ,1,2 Ying Cui ,1,2 and Xin Chai 1,2 1State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 2Tianjin Key Laboratory of TCM Chemistry and Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 3Henan Fusen Pharmaceutical Co. Ltd., Nanyang 474450, China Correspondence should be addressed to Ying Cui; [email protected] and Xin Chai; [email protected] Received 18 March 2021; Revised 19 April 2021; Accepted 3 May 2021; Published 21 May 2021 Academic Editor: Mar´ıa Jose´ Trujillo-Rodr´ıguez Copyright © 2021 Gen Xue et al. 2is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. As a clinically effective traditional Chinese medicine injection (TCMI), Shuanghuanglian injection (SHLI) is widely used in the treatment of upper respiratory tract infection and pneumonia. However, the shortage of quality analysis is a limitation that remains to be improved in the clinical application of SHLI. In this study, taking advantage of ultra-high-performance liquid chromatography tandem Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC/Q-Orbitrap-MS), 31 chemical components (eight organic acids, eleven flavonoids, five iridoid glycosides, four phenylethanoid glycosides, and three lignans) in SHLI were characterized, among which 22 components were unambiguously identified by reference compounds.
    [Show full text]